



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

JAN 13 2006


Kendrew H. Colton
Fitch, Even Tabin & Flannery
1801 K Street, N.W.
Suite 401L
Washington, DC 20006

In Re: Patent Term Extension
Application for
U.S. Patent No. 4,855,290

Dear Mr. Colton:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 4,855,290 for a period of 1,118 days. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products). Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from FDA's Electronic Forms Download Website: <http://www.fda.gov/opacom/morechoices/fdaforms/default.html> (<http://www.fda.gov/opacom/morechoices/fdaforms/FDA-3542.pdf>).

Telephone inquiries regarding this communication should be directed to Mary Till by telephone at (571)272-7755, or at Mary.Till@uspto.gov by e-mail.


Kery Fries
Senior Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: Office of Regulatory Policy
HFD - 13
5600 Fishers Lane
Rockville, MD 20857

Attention: Claudia Grillo

RE: EVOXAC® (Cevimeline HCl)
FDA Docket No.: 01E-0405

UNITED STATES PATENT AND TRADEMARK OFFICE

(12) CERTIFICATE EXTENDING PATENT TERM UNDER 35 U.S.C. § 156

(68) PATENT NO. : 4,855,290
(45) ISSUED : August 8, 1989
(75) INVENTOR : Abraham Fisher, et al.
(73) PATENT OWNER : STATE OF ISRAEL, REPRESENTED BY
PRIME MINISTER'S OFFICE, ISRAEL
INSTITUTE FOR BIOLOGICAL
RESEARCH
(95) PRODUCT : EVOXAC® (Cevimeline HCl)

This is to certify that an application under 35 U.S.C. § 156 has been filed in the United States Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 4,855,290 based upon the regulatory review of the product EVOXAC® (Cevimeline HCl) by the Food and Drug Administration. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

(94) 1,118 days

from August 8, 2006, the original expiration date of the patent, subject to the payment of maintenance fees as provided by law, with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the United States Patent and Trademark Office to be affixed this 30th day of November 2005.

A handwritten signature in black ink, appearing to read "Jon W. Dudas", is written over a faint circular stamp.

Jon W. Dudas
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office